CN101153022A - Isoquinolinium compound, producing method and application of its salt - Google Patents

Isoquinolinium compound, producing method and application of its salt Download PDF

Info

Publication number
CN101153022A
CN101153022A CNA2007101812957A CN200710181295A CN101153022A CN 101153022 A CN101153022 A CN 101153022A CN A2007101812957 A CNA2007101812957 A CN A2007101812957A CN 200710181295 A CN200710181295 A CN 200710181295A CN 101153022 A CN101153022 A CN 101153022A
Authority
CN
China
Prior art keywords
compound
salt
preparation
general structure
acid salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2007101812957A
Other languages
Chinese (zh)
Other versions
CN100422156C (en
Inventor
谢美华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Pharmaceutical Industry
Jiangsu Kanion Pharmaceutical Co Ltd
Original Assignee
Shanghai Institute of Pharmaceutical Industry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Pharmaceutical Industry filed Critical Shanghai Institute of Pharmaceutical Industry
Publication of CN101153022A publication Critical patent/CN101153022A/en
Application granted granted Critical
Publication of CN100422156C publication Critical patent/CN100422156C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention discloses a category of isoquinoline compounds or the salts as shown in the right formula, a preparation method thereof and the application in preparation of anti-arrhythmic drugs; wherein, R1 and R2 represent OCH3, OCH2Ph or are connected to be -OCH2O-. The compound pf the present invention has strong anti-arrhythmic activity, and in particular, has activity of blocking the potassium channel and the function of anti-chamber abnormity.

Description

The preparation method of Isoquinolinium compound and salt thereof and application
The present patent application is at first to file " preparation method of Isoquinolinium compound and salt thereof and application " (application number: 03129659.9; Shen feelings day: dividing an application 2003.7.2).
Technical field
The present invention relates to the preparation method of a kind of isoquinoline compound and salt thereof, and the application in preparation treatment anti-arrhythmia disease medicine.
Background technology
Sudden cardiac death (SCD) is one of cardiovascular disorder main causes of death.It is to cause clocklike that the rhythm of the heart disappears because cardiac electrophysiology is unstable that SCD produces, and the most serious is continues chamber speed (VT is vetriculartachycardia) with chamber quiver (VF, vetricalar fibrillation).
Anti-arrhythmic can divide four classes: the I class is to be the sodium channel inhibitor of representative with the Quinidine, and they mainly treat supraventricular tachycardia, and flecainide of IC class, lorcainide etc. are also effective to ventricular premature contraction, but they all have restraining effect to cardiac muscle.Extensive clinical study at CAST (Cardiac arrhthmia Suppresion Trials) finds that the medication group mortality ratio (7.7%) of such medicine is higher than control group (3.0%).This result enlightens people for the validity of antiarrhythmic drug and the revaluation of security.The II class is a beta-blocker, is mainly used in the irregular pulse that the beta-receptor hyperfunction causes, cardiac muscle is also had certain restraining effect.The IV class is a calcium channel blocker, and it suppresses flow of calcium ions and makes decreased heart rate, and cardiac muscle is also had restraining effect, and this external enwergy reflectivity causes sympathetic activation, and accelerates heart rate.III class anti-arrhythmic has over reach current potential time-histories (APD action potential duration) and effective refractory period (ERD effective refractory peridod), to the ventricular arrhythmia treatment effectively, especially life-threatening chamber speed and chamber are quivered effectively.So the emphasis of antiarrhythmic drug research turns to III class antiarrhythmic drug.
Britylium (Bretylium tosylate) is to be used for the treatment of the medicine that the chamber is fast and quiver in the chamber sixties, but it is a quaternary ammonium salt, and is oral invalid.Atlansil is the medicine that is used for the treatment of the intractable ventricular arrhythmia seventies, but because multiple side effect, clinical application is placed restrictions on.Because the complicacy of the irregular pulse cause of disease, and clinical requirement to security are so III class antiarrhythmic drug progress is slow.
From the method for applied genetics such as Tempel in 1987 and molecular cloning, from the Shaker fruit bat, clone the mutator gene of potassium channel first, almost the ligands specific of potassium channel also is found simultaneously.In addition, cell patch tongs technology application and development, so that myocardial cell's potassium channel had more comprehensively and deep understanding, thus started the upsurge of potassium channel molecular level research.Recent study finds that the myocardial cell has 8 kinds of potassium channel hypotypes, wherein export-oriented Delayed Rectifier Potassium Current (I k) retardance can over reach current potential time-histories and effective refractory period, be the main target site of III class antiarrhythmic drug.
Sotalol (Sotalol) is the nonselective beta-blocker of listing in 1974, and it has the electric physilogical characteristics of over reach current potential time-histories and effective refractory period, presents retardance I kEffect.In the research of ESVEM (Eiectrophysiloyic Versus Electrocardiongraphic Monitoring) examination bed, sotalol can reduce mortality ratio, so FDA is used for the treatment of irregular pulse in approval in 1992.The new purposes of sotalol has been started the research of the III class antiarrhythmic drug of class novel action mechanism-potassium channel retardation.
Further investigation shows I kPassage has two types, i.e. I Kr(fast passage) and I Ks(slow pathway).For I kRetarding agent treatment irregular pulse wishes to block simultaneously I KrAnd I KsBecause simple I KrRetarding agent such as sotalol, it has contrary use dependency (Reverse use-dependence RVD) and causes arrhythogenic side effect, promptly when heart rate is fast, the effect that prolongs APD slows down, and when heart rate is slow, prolong the APD effect to strengthen, therefore cause APD excessively to prolong.Block I simultaneously KrAnd I KsCan eliminate the contrary dependency of using.
Isoquinoline alkaloid extensively is present in the natural phant, and many have an important physical activity, and especially the effect aspect cardiovascular is noticeable.It is active in functions such as hypotensive, platelet aggregation-against, cardiac stimulant, diuresis and anti-arrhythmias that bisbenzylisoquinoline alkaloid in the natural phant such as Berbamine, dauricine, Tetrrine, kukoline, Neferine and monobenzyl morphinane alkaloid demethyl coclaurine and Berberine (berberine) etc. all have obvious cardiovascular.Wherein Berberine presents III class antiarrhythmic activity, clinically is used for the treatment of intractable chamber speed and chamber morning, and total effective rate reaches more than 60%, but it is a quaternary ammonium salt, and oral absorption is poor, and irregular.
In sum, to be used to prepare treatment anti-arrhythmia disease medicine be that people institute is very expected to the new isoquinoline compound of research and development.
Summary of the invention
One of technical issues that need to address of the present invention are open Isoquinolinium compound and salt thereof;
Two of the technical issues that need to address of the present invention provide the preparation method of above-mentioned isoquinoline compound;
Another technical problem that the present invention need solve is to disclose the application of described compound in preparation treatment anti-arrhythmia disease medicine, to satisfy people's needs.
Compound of the present invention is compound and the salt thereof with following general structure, comprises inorganic acid salt or organic acid salt, preferably hydrochloride:
Figure A20071018129500061
Wherein, R 1, R 2Represent OCH 3, OCH 2Ph or be connected to-OCH 2O-.
Preferred compound comprises:
1-(3-methylsulfonyl amido benzyl)-6,7-methylene-dioxy-1,2,3,4-four hydrogen isoquinoline hydrochloric acid salt (C-391);
1-(3-methylsulfonyl amido benzyl)-6-methoxyl group, 7-benzyloxy-1,2,3,4-four hydrogen isoquinoline hydrochloric acid salt (C409).
The preparation method of above-claimed cpd and salt thereof comprises the steps:
1. be raw material with substituted phenyl ethylamine (1) and substituted phenylacetic acid (2), in 170～180 ℃ of direct dehydrating condensations or substituted phenylacetic acid SOCl 2Being prepared into acyl chlorides, is solvent and substituted phenyl ethylamine (1) condensation then with the ethylene dichloride, and preparation has the compound shown in the general structure (3), and reaction expression is:
Figure A20071018129500062
2. the compound that 1. step is obtained (3) is solvent and POCl with the chloroform 3Reflux and react down, obtain to have the compound shown in the general structure (4), reaction expression is:
Figure A20071018129500063
3. the compound that 2. step is obtained (4) is solvent and NaBH with methyl alcohol 4React, obtain to have the compound shown in the general structure (5), reaction expression is:
Figure A20071018129500071
4. the compound that 3. step is obtained (5) stirs under room temperature with EtOH-HX and separates out precipitation and be converted into corresponding salt; Wherein, X is a halogen.
Compound of the present invention and hydrochloride thereof, mineral acid or organic acid salt can be used for preparing antiarrhythmic medicine.Test-results shows that The compounds of this invention presents very strong antiarrhythmic activity, especially have the retardance potassium channel activity and present the not normal effect of anti-chamber property rule.
(1) electricity irritation is caused that shrink the guinea pig in vitro left atrium and the spontaneous dancing influence in right atrium (seeing Table 1);
(2) the guinea pig left atrium myoelectricity that exsomatizes is stimulated the influence (seeing Table 2) that causes FRP (FRP);
(3) chamber that causes of anti-ouabain early, a short battle array chamber speed, the quiver effect (seeing Table 3) of cavy whole animal model of chamber speed and chamber;
(4) use patch clamp technique, carry out the research (seeing Table 4) of potassium channel blocking effect;
Compound of the present invention can composition the mode of form by oral, vein, Transdermal absorption be applied to the patient that need treat.Said composition contains the arbitrary described compound of the general structure I～VIII that treats significant quantity, and one or more pharmaceutically acceptable carriers, said carrier is meant the carrier of medicine and pharmacology field routine, for example, thinner such as water etc., weighting agent such as starch etc., tackiness agent such as derivatived cellulose etc., or other sweeting agents, flavouring agent etc.
Amount of application of the present invention can change according to the type of route of administration, patient's age, body weight, disease and severity etc., and its per daily dose is generally 0.1～10mg/kg body weight.
Table 1 pair electricity irritation causes that the guinea pig left atrium that exsomatizes is shunk and the influence of the spontaneous jumping in right atrium
Figure A20071018129500072
Figure A20071018129500081
From the visible compound S IPI926 of last table, 1123,1127 and 1124 have the spontaneous dancing activity in the right atrium of inhibition, IC 50Value is respectively: 7.09,3.91,3.72 and 6.3 μ M.The restraining effect that compares the left atrium with verapamil (Verapamie) is little.1127 pairs of left atrium convergent forces of compound S IPI have certain enhancement.
Table 2 compound stimulates the influence that causes FRP (FRP) to the guinea pig left atrium myoelectricity that exsomatizes
Figure A20071018129500082
Figure A20071018129500091
*-effective refractory period shortens.
From last table visible Compound C-391, C-409, C-312, C-602, C-491 compare with sotalol with SIPI 926 has the activity that prolongs effective refractory period.
The anti-ouabain of table 3 causes the test of cavy ventricular arrhythmia
Sample Dosage mg (mmol)/kg Ouabain dosage (μ g/kg)
Ventricular premature contraction Short battle array chamber speed Chamber speed Quiver in the chamber
Physiological saline 2m/kg 144.8 156.1 167.4 189.3
Sotalol 6.17(0.02) 206.3 230.4 240.2 298.7
SIPS-926 3.6(0.01) 183.4 188.1 192.7 232.9
C-391 3.9(0.01) 200.1 240.3 248.6 291.0
C-409 9.7(0.02) 208.5 219.6 245.3 308.0
C-602 8.7(0.02) 202.1 222.6 234.1 283.4
C-312 4.2(0.01) 177.3 194.1 210.2 253.8
C-491 10.15(0.02) 187.0 212.9 237.8 292.2
From the visible compound S IPI-926 of last table, C-391, C-409, C-602, C-312 compares with sotalol with C-491, presents significant anti-ventricular arrhythmia activity.
SIPI-926 all shows good antiarrhythmic activity, and in the whole animal model discrimination, finds that it has III class antiarrhythmic activity in suppressing the ventricular arrhythmia model that spontaneous dancing model in right atrium and anti-ouabain cause.In order to inquire into its mechanism of antiarrhythmic action, utilize patch clamp technique, and compare with sotalol, carried out the research of potassium channel blocking effect.The results list is as follows:
Table 4-1 sotatol 100 μ mol/l are to Delayed Rectifier Potassium Current (I Kr) process action time (pA)
control Sotalol
1min 2min 3min
1 27.01 20.45 16.19 10.75
2 21.24 13.44 9.21 5.37
3 33.47 25.9 18.21 12.11
4 26.85 23.14 19.74 15.32
M 27.14 20.73 15.84 11.14
P 0.138 0.016 0.003
Table 4-2SIPI-926100 μ mol/L is to I KrProcess action time (pA)
control SIPI 926
1min 2min 3min
1 19.0 9.5 0 * 0 *
2 31.2 12.5 0 * 0 *
3 31.2 15.6 0 * 0 *
M 27.1 12.5
P 0.03 0.03 0.02
*0 is all to block potassium current, and cell is not dead.
Table 4-3 SIPI-926 is to I KsConcentration dependent effect (pA)
control SIP-926
1×10 -4M 1×10 -5M 1×10 -6M
1 925 412 710 770
2 632 357 566 589
3 721 388 531 651
4 895 400 634 547
M 793 389 610 639
P 0.006 0.02 0.1127
Conclusion: SIPI-926 is to I KrRetardation is arranged, and have time-dependent manner.When 100 μ mol concentration, SIPI-926 is when 1min, to I KrInhibiting rate and suitable during sotalol 4min, and when 2min, suppress I fully Kr, illustrate that SIPI-926 is to I KrRestraining effect stronger than sotalol.What is more important SIPI-926 is to I KsAlso present the dependent retardation of tangible solubility.SIPI-926 is to I KrAnd I KsRetardation is all arranged, and this is that current III class antiarrhythmic drug is desirable.And sotalol only blocks I Kr, prompting is on the mechanism of action, and SIPI-926 is more superior than sotalol.
As can be seen from the above results, the antiarrhythmic effect of SIPI-926 is because it has blocked I KrAnd I KsThereby over reach current potential time-histories and effective refractory period show its III class antiarrhythmic drug effect.From the introduction of front as can be known, block I simultaneously KrAnd I Ks, can eliminate the contrary dependency of using, significantly reduce the proarrhythmia side effect, be one of main direction of current antiarrhythmic drug research.
Embodiment
Embodiment 1
1-(2, the 5-dimethoxy-benzyl)-6,7-methylene-dioxy-1,2,3,4-four hydrogen isoquinoline hydrochloric acid salt SIPI 926
(1) 16.3g (0.1mol) homopiperony lamine and 19.0g (0.1mol) 2.5-dimethoxyphenylacetic acid are mixed, in 170-180 ℃ of heating 4 hours, cooling, after being dissolved in chloroform, use 2NHCl successively, 2NNaOH and water washing, anhydrous magnesium sulfate drying removes solvent under reduced pressure, residuum EtOH-H 2The O recrystallization gets 22.1gN-(3,4-methylene-dioxy styroyl)-3,4-dimethoxy phenylacetamide, yield 65%, fusing point 119-120 ℃.
Ultimate analysis C 19H 21NO 5Calculated value %:C 66.74, H 5.87, and N 4.07
Measured value %:C 66.46, H 6.16, and N 4.08
(2) above-mentioned acid amides 17g (0.05mol) is dissolved in the dry chloroform, add the 26ml phosphorus oxychloride, refluxed 4 hours, remove solvent and excessive phosphorus oxychloride under reduced pressure, the residuum petroleum ether, obtain solid, ethyl alcohol recrystallization gets 13.8g 1-(2, the 5-Dimethoxyphenyl)-6.7-methylene-dioxy-3, the 4-dihydro-isoquinoline hydrochloride, yield 85%, fusing point 197-198 ℃ (decomposition).
Ultimate analysis C 19H 20NO 4Cl calculated value %:C 63.03, H 5.56, and N 4.07, and Cl 9.74
Measured value %:C 63.07, H 5.57, and N 3.87, and Cl 9.80
(3) above-mentioned dihydro-isoquinoline hydrochloride 9.6g (0.03mole) is dissolved in the 200ml methyl alcohol, is chilled to 5 ℃, divide 3 each 1g to add sodium borohydride, finish, stirring at room 1-2 hour, remove solvent under reduced pressure, add 100ml water, chloroform extraction, washing, anhydrous magnesium sulfate drying, the chloroformic solution of filtering siccative drips EtOH-HCl to PH1-2, remove solvent under reduced pressure, use 95% ethyl alcohol recrystallization, get 7.3g SIPI 926, yield 75%, fusing point 237-240 ℃ (decomposition)
Ultimate analysis C 19H 22NO 4Cl calculated value %:C 62.72, H 6.09, and N 3.85, and Cl 9.74
Measured value %:C 62.91, H 6.38, and N 3.99, and Cl 9.88
Embodiment 2
1-(4-methoxy-benzyl)-6-methoxyl group-7-benzyloxy-1,2,3,4-four hydrogen isoquinoline hydrochloric acid salt SIPI 1124
(1) be that raw material makes corresponding amide by example one (1) operation with 3-methoxyl group-4-benzyloxy phenylethylamine and 4-methoxyphenylacetic acid.
(2) be that raw material makes corresponding dihydro-isoquinoline hydrochloride by embodiment 1 (2) operation with above-mentioned acid amides
(3) be that raw material makes SIPI 1124, fusing point 176-177 ℃ by example one (3) operation with above-mentioned dihydro-isoquinoline hydrochloride.
Ultimate analysis C 25H 28NO 3ClH 2O calculated value %:C 67.63, H 6.81, and N 3.16, and Cl 7.99
Measured value %:C 67.93, H 7.00, and N 2.85, and Cl 8.19
Embodiment 3
1-(3-methylsulfonyl amido benzyl)-6,7-methylene-dioxy-1,2,3,4-four hydrogen isoquinoline hydrochloric acid salt C-391
(1) 8.5g (0.047mol) 3-nitrophenyl-acetic acid, 16ml SOCl 2, 16ml benzene is mixed, behind the reflux 4h, removes solvent and excessive SOCl under reduced pressure 2Get 3-oil of mirbane Acetyl Chloride 98Min..
8g (0.04mol) homopiperony lamine is dissolved in the 60ml ethylene dichloride,, drips 10% the NaOH solution and the dichloroethane solution of 7.8g (0.039mol) 3-oil of mirbane Acetyl Chloride 98Min. simultaneously in 0～5 ℃, control PH8-9 finishes, stirring at room reaction 4h, separate out solid, filter collection, 5%HCl washing, washing, drying, ethyl alcohol recrystallization, get 12.5gN-(3,4-methylene-dioxy styroyl)-and 3-oil of mirbane ethanamide, yield 86%, fusing point 128-130 ℃.
(2) 10g iron powder and 5% NH 4Cl solution 50ml is mixed, in 100 ℃ of stirrings 20 minutes, is chilled to 60 ℃ then, adds 10g (0.03mol) N-(3,4-methylene-dioxy styroyl)-3-oil of mirbane ethanamide and 10ml ethanolic soln.In 60 ℃ of stirring reactions 3 hours.Be chilled to room temperature, add 5%NaHCO 320ml, methylene dichloride 60ml, continuation was stirred 10 minutes, filtered, and divide and get organic layer, washing, drying removes solvent under reduced pressure, gets 8.0g N-(3,4-methylene-dioxy styroyl)-3-amido phenylacetamide, yield 90%, fusing point 155-157 ℃.
(3) 8.5g (0.028mol) N-(3,4-methylene-dioxy styroyl)-3-amido ethanamide and 20ml pyridine are mixed, are chilled to 0 ℃, drip 3.5g (0.03mol) methylsulfonyl chloride, finish, stirring at room reaction 20 hours, Dropwise 5 %HCl to PH2-3 separates out solid, continues to stir 10 minutes, filter collection solid, washing, drying, ethyl alcohol recrystallization gets 9.7g N-(3,4-methylene-dioxy styroyl)-3-Toluidrin yl acetamide, yield 92.4%, fusing point 144-145 ℃.
(4) 5g N-(3,4-methylene-dioxy styroyl)-3-Toluidrin yl acetamide, 15ml POCl 3Mixed with the 30ml chloroform, reflux 3.5 hours removes solvent and excessive POCl then under reduced pressure 3, the residuum petroleum ether, ethyl alcohol recrystallization gets 1-(3-methylsulfonyl amido benzyl)-6,7-methylene-dioxy-3,4-dihydro-isoquinoline hydrochloride 5.0g, yield 95%, fusing point 241-243 ℃.
(5) 1.0g 1-(3-methylsulfonyl amido benzyl)-6,7-methylene-dioxy-3, the 4-dihydro-isoquinoline is dissolved in the 30ml methyl alcohol, presses example one (3) operation, gradation adds the reduction of 1g sodium borohydride, becomes hydrochloride with EtOH-HCl, makes C-3910.8g, yield 84.1%, molten some 256-257 ℃, MS:M +360.
Embodiment 4
1-(3-methylsulfonyl amido benzyl)-6-methoxyl group, 7-benzyloxy-1,2,3,4-four hydrogen isoquinoline hydrochloric acid salt C409
(1) be that raw material makes N-(3-methoxyl group-4-benzyloxy styroyl)-3-oil of mirbane ethanamide by embodiment 3-(1) and the condensation of 3-nitrophenyl-acetic acid with 3-methoxyl group-4-benzyloxy phenylethylamine.
(2) above-mentioned acid amides is used Fe-NH by example three-(2) 4The Cl reduction makes N-(3-methoxyl group-4-benzyloxy styroyl)-3-amido phenylacetamide.
(3) above-mentioned acid amides makes N-(3-methoxyl group-4-benzyloxy styroyl)-3-methylsulfonyl amido phenylacetamide by example three-(3) and methylsulfonyl chloride reaction.
(4) above-mentioned acid amides is pressed example three-(4) and POCl 3Reaction makes 1-(3-methylsulfonyl amido benzyl)-6-methoxyl group-7-benzyloxy-3,4-dihydro-isoquinoline hydrochloride.
(5) above-mentioned dihydro-isoquinoline makes 1-(3-methylsulfonyl amido benzyl)-6-methoxyl group-7-benzyloxy-1,2,3,4-tetrahydroisoquinoline by example-(5) through the sodium borohydride reduction.Make hydrochloride C409 with the EtOH-HCl salify, yield 80.3%, fusing point 202-204 ℃, MS:M +452.
Embodiment 5
1-(2, the 5-dimethoxy-benzyl)-4-sec.-propyl-6,7-dimethoxy-1,2,3,4-four hydrogen isoquinoline hydrochloric acid salt C312
(1) α-sec.-propyl-3, the 4-dimethoxybenzeneacetonitrile
30ml 40%NaOH is splashed into 10g (0.057mol) 3 in room temperature, in the mixed solution of 4-dimethoxybenzeneacetonitrile, 26ml methyl-sulphoxide and 9.24g (0.081mol) bromo propane, finish, in stirring at room 4.5 hours, add water 100ml, tell organic layer, water layer extracts with toluene 30ml * 3, merges organic layer, is washed to neutrality, anhydrous magnesium sulfate drying, remove solvent under reduced pressure and get 9.4g, yield 81% is placed after fixing, fusing point 46-48 ℃, MS:M +219.
(2) 3.4-dimethoxy-β-isopropyl benzene ethamine
With the 100ml tetrahydrofuran (THF), 24.66g (0.18mol) aluminum chloride is mixed, stirs a moment in ice is molten, and adding potassium boron hydrogen 9.95g (0.18mol) was in stirring at room 1 hour.Add 8g (0.0365mol)-α-sec.-propyl-3, the 30ml tetrahydrofuran solution of 4-dimethoxybenzeneacetonitrile.Finish, after 1 hour, back flow reaction is 1 hour again in stirring at room.Remove solvent under reduced pressure, use the 1N hcl acidifying, methylene dichloride 30ml * 3 washings alkalizes to PH11-12 with 20% sodium hydroxide, and extract methylene dichloride 60ml * 3, washing, and anhydrous magnesium sulfate drying removes solvent under reduced pressure, gets 4.32g, yield 53%.Not purifiedly be directly used in the synthetic of following acid amides.
(3) N-(3,4-dimethoxy-β-isopropyl phenyl)-2,5-dimethoxy phenylacetamide
With 2,5-dimethoxyphenylacetic acid 3.46g (0.18mol) is dissolved in the 40ml exsiccant ethylene dichloride, drips 6.3g (0.54mol) sulfur oxychloride in 0 ℃, finishes, and in stirring at room 30 minutes, is warming up to 40-45 ℃ of stirring reaction afterwards 4 hours.Remove solvent and excessive sulfur oxychloride under reduced pressure, get 2,5-dimethoxy Acetyl Chloride 98Min..
The 20ml diethyl ether solution of 1N sodium hydroxide 20ml (0.02mol) and above-mentioned acyl chlorides is splashed into 4g (0.016mol) 3 simultaneously in 0 ℃, in the 20ml diethyl ether solution of 4-dimethoxy-β-isopropyl benzene ethamine, control PH8-9 finishes, in 0 ℃ stir 2 hours after, in stirring at room 4 hours.Separate out solid, the filter collection is washed to neutrality, drying.Heavy 5.1g, yield 59.4%, fusing point 78-80 ℃, MS:M +401.
(4) 1-(2, the 5-dimethoxy-benzyl)-4-sec.-propyl-6,7-dimethoxy-3,4-dihydro-isoquinoline hydrochloride
4.1g (0.01mol) above acid amides, 60ml ethylene dichloride and 10ml phosphorus oxychloride are mixed, reflux 3.5 hours, remove solvent under reduced pressure, use petroleum ether three times, use the alcohol-ether recrystallization, get 2.1g, 180-181 ℃ of yield 41.5%. fusing point, MS:M +383.
(5) Compound C 312
2.1g (4.4mmol) above-mentioned dihydro-isoquinoline hydrochloride is dissolved in the 20ml methyl alcohol, the ice bath cooling adds 0.8g (0.02mol) sodium borohydride, stirring at room 4 hours removes solvent under reduced pressure, adds water 100ml, extract with ethylene dichloride 30ml * 3, wash 2 times, anhydrous magnesium sulfate drying removes solvent under reduced pressure, with EtOH-HCl solution salify, the filter collection, heavy 1.2g, yield 58.1%.Molten some 178-179 ℃, MS:M +385.
Embodiment 6
2-[1-(to a Toluidrin phenoxyl)-2-hydroxyl-propyl group]-6,7-dimethoxy-1,2,3,4-four hydrogen isoquinoline hydrochloric acid salt C602
(1) 6,7-dimethoxy-1,2,3, the 4-four hydrogen isoquinoline hydrochloric acid salt
With 3,4-dimethoxy-phenylethylamine 1.8g (10mmol), Paraformaldehyde 96 0.30g (10mmol) and 98% formic acid 20ml mix, in 40～60 ℃ of stirring reaction 1.5h, be chilled to room temperature, remove formic acid under reduced pressure, get oily matter, add water 20ml, transfer PH8-9 with ammoniacal liquor, extract methylene dichloride 20ml * 3, water 10ml * 3 washings, anhydrous magnesium sulfate drying, remove the appearance agent under reduced pressure, get oily matter, with ethyl acetate 30ml dissolving, down in the ice bath cooling, add EtOH-HCl, fold white solid, filter collection, ethyl acetate washing, dry, heavy 2.10g, yield 90.0%, 255～256 ℃ of fusing points.
(2) 2-[1-(right-nitro-phenoxy)-2-hydroxyl-propyl group]-6,7-dimethoxy-1,2,3,4---four hydrogen isoquinoline hydrochloric acid salt
Above-mentioned hydrochloride 1.0g (4.36mmol) 1-chloro-2-(right-nitro-phenoxy)-2-propyl alcohol 1.0g (4.36mmol) and K 2CO 31.2g (8.72mmol), KI 0.7g (4.36mmol) and 50ml ethanol mixture, refluxed 8 hours, be chilled to room temperature, filtering is not tolerant, steams and removes ethanol, adds 30ml water, extract chloroform 30ml * 3, washing, anhydrous magnesium sulfate drying is used the EtOH-HCl salify, get 1.1g, yield 59.4%, 122～124 ℃ of fusing points, MS:388.
(3) 2-[1-(right-the amido phenoxy group)-2-hydroxyl-propyl group]-6,7-dimethoxy-1,2,3,4---four hydrogen isoquinoline hydrochloric acid salt
With free alkali 0.8g (2.06mmol), the iron powder 1.0g (15mmol) of above-mentioned hydrochloride, NH 4Cl 0.5g (9.2mmol) puts in the 250ml three-necked bottle, adds 75% aqueous ethanolic solution 60ml, and backflow 4h is chilled to room temperature, adds Na 2CO 31.5g and acetate acetate 50ml, support was mixed 30 minutes, and the filtering insolubles removes ethanol and ethyl acetate under reduced pressure, extract ethyl acetate 50ml * 3, anhydrous magnesium sulfate drying removes ethyl acetate under reduced pressure, and the post layer separates (or directly using the EtOH-HCl salify), get 0.61g, yield 85.9%, mp214～216 ℃, MS:M +358.
(4)C602
The free alkali 0.5g (1.4mmol) of above-mentioned hydrochloride is dissolved in the 20ml dry pyridine, adds trimethylchlorosilane 2.0ml (16.0mmol) under stirring at room, stirring reaction 10 hours added methylsulfonyl chloride 0.23ml (2.6mmol) stirring at room 7 hours.Add H 2O 2ml transfers PH1～2 with concentrated hydrochloric acid, uses NH again 4OH transfers PH8-9, CH 2Cl 2Extract 30ml * 3, washing, and anhydrous magnesium sulfate drying, the post layer separates, (eluent ethyl acetate).Use the EtOH-HCl salify, get 0.32g, yield 48.5%, 209～212 ℃ of fusing points, MS:M +437.
(5) 1-chloro-2-(right-nitro-phenoxy)-2-propyl alcohol
Get to nitre phenol 28.0g (0.2mol) sodium hydroxide 8.0g (0.2mol) and H 2O 75ml places the 250ml reaction flask, and behind the backflow 4h, solid all dissolves, and drips 1-epichlorohydrin 32ml (0.4mol) down in refluxing, add in the 1h, continue back flow reaction 4h, be chilled to room temperature, use ethyl acetate 200ml, extract 100ml * 2, washing, anhydrous magnesium sulfate drying, decompression.Steaming desolventizes.The post layer separates (eluent CH 2Cl 2: sherwood oil (30～60 ℃)=3: 1), get 25.4g (oily matter), yield 55.0%.
Embodiment 7
2-[1-(right-the amido phenoxy group)-2-hydroxyl-propyl group]-6-methoxyl group-7-benzyloxy-1,2,3,4-four hydrogen isoquinoline hydrochloric acid salt C491
(1) be that raw material makes 6-methoxyl group-7-benzyloxy-1,2,3 by example 6-(1) with 3-methoxyl group-4-benzyloxy phenylethylamine, 4-four hydrogen isoquinoline hydrochloric acid salt, yield 65%, fusing point 214-215 ℃.
(2) be raw material with above-mentioned hydrochloride, make 2-[1-(p-nitrophenyl oxygen base)-2-hydroxyl-propyl group by embodiment 6-(2)]-6-methoxyl group-7-benzyloxy-1,2,3,4-four hydrogen isoquinoline hydrochloric acid salt, yield 86.5%, MS:M +465.Fusing point 158-161 ℃.
(3) be that raw material prepares C491 by embodiment 6-(3) with above-mentioned hydrochloride, yield 84,8% (contains 2H 2O and 1HCl salt).Fusing point 208-211 ℃ (decomposition), MS:M +435.
Contain compound of the present invention, add the multiple formulation that different auxiliary material is made tablet, capsule, preparation capable of permeating skin, sustained release preparation and injection.With different route of administration medications, to satisfy clinical needs.
Embodiment 8
Injection
Prescription SIPI 926 2.5～5g
Phenylcarbinol 9～18g
Water for injection adds to 1000ml
Preparation technology: accurately take by weighing SIPI926 by recipe quantity and place a container, add an amount of water for injection, stirring makes molten entirely, presses recipe quantity and adds phenylcarbinol, adds to the full amount of water for injection, and solution is through 0.45 μ m filtering with microporous membrane.The solution embedding is (1ml contains main ingredient 2mg) in glass ampoule, and preparation was through flowing steam sterilization 30 minutes.
Embodiment 9
Capsule
Prescription SIPI 926 30mg
Starch 40mg
Lactose 120mg
Talcum powder 10mg
Preparation technology: SIPI 926 is worn into fine powder, cross 100 order nylon mesh.Former, auxiliary material fine powder are fully mixed evenly, after 60 mesh sieve secondaries.To mix during former uniformly, auxiliary material fine powder incapsulates, every capsules contains main ingredient 30mg.
Embodiment 10
Slow releasing tablet
Prescription: immediate release section slow-released part
SIPI 926 15g SIPI 926 15g
Lactose 60 dextrin 3g
Starch 20g gum arabic 1g
The low hydroxyl cane sugar powder 1g that replaces
Propyl cellulose 10g starch 15g
An amount of Magnesium Stearate 15g of 7% starch slurry
Magnesium Stearate 1g shellac solution 20ml
Ethanol is an amount of
It is an amount of to heat up in a steamer water
Preparation technology:
Raw material SIPI 926 is worn into fine powder, cross 100 mesh sieves.The fine powder of raw material and auxiliary material is evenly mixed, cross 60 mesh sieve secondaries, add 7% starch slurry, make particle with 20 mesh sieves, in 50～55 ℃ of convection oven dryings, make the immediate release section dried particles.By the same method slow-released part is made dried particles.The dried particles of quick-release and slowly-releasing two parts is mixed, sieve 2 times through 16 mesh sieves, add the Magnesium Stearate mixing, compressing tablet, every contains main ingredient 5mg, 10mg, 15mg.

Claims (8)

1. Isoquinolinium compound or its salt, it is characterized in that: described compound is for having following general structure:
Figure A2007101812950002C1
Wherein, R 1, R 2Represent OCH 3, OCH 2Ph or be connected to-OCH 2O-.
2. the described compound of claim 1 is characterized in that, described salt comprises inorganic acid salt or organic acid salt.
3. compound according to claim 2 is characterized in that, described salt is hydrochloride.
4. compound according to claim 3 is characterized in that the salt of being addressed is:
1-(3-methylsulfonyl amido benzyl)-6,7-methylene-dioxy-1,2,3,4-four hydrogen isoquinoline hydrochloric acid salt (C-391).
5. compound according to claim 3 is characterized in that the salt of being addressed is:
1-(3-methylsulfonyl amido benzyl)-6-methoxyl group, 7-benzyloxy-1,2,3,4-four hydrogen isoquinoline hydrochloric acid salt (C409).
6. the preparation method of described compound of claim 1 and salt thereof is characterized in that comprising the steps:
1. be raw material with substituted phenyl ethylamine (1) and substituted phenylacetic acid (2), in 170～180 ℃ of direct dehydrating condensations or substituted phenylacetic acid SOCl 2Being prepared into acyl chlorides, is solvent and substituted phenyl ethylamine (1) condensation then with the ethylene dichloride, and preparation has the compound shown in the general structure (3), and reaction expression is:
Figure A2007101812950002C2
2. the compound that 1. step is obtained (3) is solvent and POCl with the chloroform 3Reflux and react down, obtain to have the compound shown in the general structure (4), reaction expression is:
3. the compound that 2. step is obtained (4) is solvent and NaBH with methyl alcohol 4React, obtain to have the compound shown in the general structure (5), reaction expression is:
Figure A2007101812950003C2
4. the compound that 3. step is obtained (5) stirs under room temperature with EtOH-HX and separates out precipitation and be converted into corresponding salt; Wherein, X is a halogen.
7. contain claim 1～4 each the described compound and the salt thereof for the treatment of significant quantity, and the pharmaceutical composition of pharmaceutically acceptable carrier.
8. each described compound of claim 1～4 and salt thereof the application in the antiarrhythmic medicine of preparation treatment.
CNB2007101812957A 2003-07-02 2003-07-02 Isoquinolinium compound, producing method and application of its salt Expired - Lifetime CN100422156C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB031296599A CN100404509C (en) 2003-07-02 2003-07-02 Isoquinoline compound, preparation method and application of salt thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB031296599A Division CN100404509C (en) 2003-07-02 2003-07-02 Isoquinoline compound, preparation method and application of salt thereof

Publications (2)

Publication Number Publication Date
CN101153022A true CN101153022A (en) 2008-04-02
CN100422156C CN100422156C (en) 2008-10-01

Family

ID=34469396

Family Applications (5)

Application Number Title Priority Date Filing Date
CNB2007101812942A Expired - Fee Related CN100494180C (en) 2003-07-02 2003-07-02 Preparation method and uses of isoquinolinium compound and its salt
CN200710165708A Expired - Fee Related CN100595195C (en) 2003-07-02 2003-07-02 Preparation method and application of isoquinoline componds and salts thereof
CNB2007101657078A Expired - Lifetime CN100572360C (en) 2003-07-02 2003-07-02 The preparation method of Isoquinolinium compound and salt thereof and application
CNB2007101812957A Expired - Lifetime CN100422156C (en) 2003-07-02 2003-07-02 Isoquinolinium compound, producing method and application of its salt
CNB031296599A Expired - Lifetime CN100404509C (en) 2003-07-02 2003-07-02 Isoquinoline compound, preparation method and application of salt thereof

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CNB2007101812942A Expired - Fee Related CN100494180C (en) 2003-07-02 2003-07-02 Preparation method and uses of isoquinolinium compound and its salt
CN200710165708A Expired - Fee Related CN100595195C (en) 2003-07-02 2003-07-02 Preparation method and application of isoquinoline componds and salts thereof
CNB2007101657078A Expired - Lifetime CN100572360C (en) 2003-07-02 2003-07-02 The preparation method of Isoquinolinium compound and salt thereof and application

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB031296599A Expired - Lifetime CN100404509C (en) 2003-07-02 2003-07-02 Isoquinoline compound, preparation method and application of salt thereof

Country Status (1)

Country Link
CN (5) CN100494180C (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104693115A (en) * 2013-12-06 2015-06-10 上海医药工业研究院 A chiral tetrahydroisoquinoline derivative or salts thereof, and a preparing method and uses thereof

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101468991B (en) * 2007-12-28 2011-04-27 上海医药工业研究院 Isoquinolinium compound or its salt, pharmaceutical composition containing the same, preparation and use thereof
CN101468995B (en) * 2007-12-28 2011-04-06 上海医药工业研究院 Isoquinolinium compound or its salts, pharmaceutical composition containing the same, preparation and use thereof
CN101468992B (en) * 2007-12-28 2010-12-08 上海医药工业研究院 Isoquinolinium compound or salts thereof, pharmaceutical composition containing the same, preparation and use thereof
CN101468993B (en) * 2007-12-28 2010-10-13 上海医药工业研究院 Isoquinolinium compound or its salts, pharmaceutical composition containing the same, preparation and use thereof
CN103508960B (en) * 2012-06-29 2017-12-12 江苏先声药业有限公司 Benzheterocyclic derivatives
US9908887B2 (en) * 2012-12-21 2018-03-06 Epizyme, Inc. PRMT5 inhibitors and uses thereof
CN107793356B (en) * 2016-08-31 2021-07-27 上海医药工业研究院 Tetrahydroisoquinoline salt derivative and preparation method and application of crystal thereof
JP6823714B2 (en) * 2016-08-31 2021-02-03 チャイナ ステート インスティチュート オブ ファーマスーティカル インダストリー Crystals of salt of tetrahydroisoquinoline, pharmaceutical composition containing the crystals, and method for producing the crystals.
CN107778232B (en) * 2016-08-31 2021-05-28 上海医药工业研究院 Tetrahydroisoquinoline salt derivative and preparation method and application of crystal thereof
CN112920116A (en) * 2019-12-06 2021-06-08 上海医药工业研究院 Preparation method of papaverine
CN113456639B (en) * 2020-03-31 2024-01-26 江苏康缘药业股份有限公司 Anti-arrhythmia pharmaceutical composition and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1045785A (en) * 1989-03-21 1990-10-03 国家医药管理局上海医药工业研究院 There are isoquinoline 99.9, quinazolone and the protoberberine derivative of the effect of treatment cardiovascular disorder synthetic
CN1045785C (en) * 1996-02-06 1999-10-20 山东省南墅石墨矿 High-impedance internal conductive coating for cathode-ray tube and preparing process thereof
EP1155001A4 (en) * 1999-02-22 2003-05-28 Lion Bioscience Ag Isoquinoline derivatives and isoquinoline combinatorial libraries

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104693115A (en) * 2013-12-06 2015-06-10 上海医药工业研究院 A chiral tetrahydroisoquinoline derivative or salts thereof, and a preparing method and uses thereof
CN104693115B (en) * 2013-12-06 2017-06-16 上海医药工业研究院 The derivative of chiral tetrahydroisoquinoline or its salt and its production and use

Also Published As

Publication number Publication date
CN100404509C (en) 2008-07-23
CN100422156C (en) 2008-10-01
CN100572360C (en) 2009-12-23
CN101407494A (en) 2009-04-15
CN101153021A (en) 2008-04-02
CN100595195C (en) 2010-03-24
CN1566098A (en) 2005-01-19
CN100494180C (en) 2009-06-03
CN101407495A (en) 2009-04-15

Similar Documents

Publication Publication Date Title
CN100494180C (en) Preparation method and uses of isoquinolinium compound and its salt
Jia-Qing Cardiovascular pharmacological effects of bisbenzylisoquinoline alkaloid derivatives
CN105814067B (en) The prodrug of pyridine keto-amide as sodium channel modulators
Smith et al. Properties of the interaction between ketamine and opiate binding sites in vivo and in vitro
JP5738775B2 (en) Treatment of dyskinesia-related disorders
US20050020597A1 (en) Aryl and heteroaryl substituted tetrahydroisoquinolines and use thereof
CN107021951A (en) SGC stimulants
CN104271581B (en) 2-(pyridine-2 base)-1,7-diaza spiro [4.4] nonyl-6-ketonic compound as voltage-gated sodium channel modulator
Lionte et al. Toxic and drug-induced changes of the electrocardiogram
CN101619038A (en) Isoquinoline compound or salt thereof, medicinal composition, preparation method and application thereof
CN104693115B (en) The derivative of chiral tetrahydroisoquinoline or its salt and its production and use
CN106456573A (en) Novel functionalized 1,3-benzene diols for the treatment of hepatic encephalopathy and their method of use
JPH08511004A (en) 1,2,3,4-Tetrahydroquinoline-2,3,4-trione-3 or 4-oximes and their use
CN103382214A (en) Tanshinone IIA phosphate phenolic ester derivative and preparation process thereof
CN104292226A (en) Paliperidone amino acid derivatives and application thereof
CN101468995B (en) Isoquinolinium compound or its salts, pharmaceutical composition containing the same, preparation and use thereof
Fanciullacci et al. Hypersensitivity to lysergic acid diethylamide (LSD-25) and psilocybin in essential headache
CN100361943C (en) 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-methoxypyridin-3-yl)propyl] benzamide, its use as a medicament, and pharmaceutical preparations comprising it
CN1255917A (en) Anti-convulsant isoquinolyl-benzamide derivatives
CN101468993B (en) Isoquinolinium compound or its salts, pharmaceutical composition containing the same, preparation and use thereof
CN101619065B (en) Isoquinoline compound or salt thereof, medicinal composition, preparation method and application thereof
EP2099303A1 (en) Therapeutic tetrahydroisoquinoline-based compositions for cancer therapy
CN101619066A (en) Isoquinoline compound or salt thereof, medicinal composition, preparation method and application thereof
CN103373959A (en) Preparation method of cis-benzyl isoquinoline compound and application thereof
CN102993208B (en) Noradrenaline and selective serotonin receptor blocking agent and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Effective date: 20110830

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 200040 HUANGPU, SHANGHAI TO: 222047 LIANYUNGANG, JIANGSU PROVINCE

TR01 Transfer of patent right

Effective date of registration: 20110830

Address after: 222047 No. 58 North Taishan Road, Lianyungang economic and Technological Development Zone, Jiangsu, China

Co-patentee after: SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY

Patentee after: JIANGSU KANION PHARMACEUTICAL Co.,Ltd.

Address before: 200040 Beijing West Road, Shanghai, No. 1320

Patentee before: Shanghai Institute of pharmaceutical industry

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20081001